• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Low-dose aspirin reduces incidence of preterm preeclampsia in high-risk pregnancies: The ASPRE trial

byJames RoebkerandDayton McMillan
August 18, 2017
in Cardiology, Chronic Disease, Emergency, Endocrinology, Nephrology, Neurology, Obstetrics, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Low-dose aspirin significantly reduced the incidence of preterm preeclampsia in women identified as high-risk for preeclampsia using a screening protocol that combined maternal factors with biochemical measurements at 11-13 weeks of gestation.

2. No significant differences in adverse outcomes were found in women given low-dose aspirin compared to placebo.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Preeclampsia is a morbid condition of pregnancy which can lead to preterm birth. Prior research has shown aspirin to be associated with lower incidence of preeclampsia in some study populations, leading to low-dose aspirin now being standard of care for high-risk pregnancies, though early identification of such pregnancies remains a challenge. The Combined Multimarker Screening and Randomized Patient Treatment with Aspirin for Evidenced-Based Preeclampsia Prevention (ASPRE) trial examined whether prophylactic low-dose aspirin starting near the end of the first-trimester reduced the risk of preeclampsia in women identified as high-risk based on a priori maternal factors and biochemical measurements assessed at 11 to 13 weeks of gestation. The primary endpoint, delivery with preeclampsia before 37 weeks of gestation, was significantly reduced in high-risk women taking low-dose aspirin compared to those treated with placebo. No significant differences in secondary endpoints identifying adverse outcomes, such as death and neonatal complications, neonatal therapy, and poor fetal growth at various times during gestation, were demonstrated between study groups. This study indicates the benefit of low-dose aspirin in women determined to be at high-risk of preeclampsia in reducing incidence of preeclampsia.

This is a large, double-blind, randomized, multicenter trial examining the prophylactic use of aspirin in a cohort of women screened for preterm preeclampsia. The multi-metric screening approach helped overcome the current obstetric challenge of identifying women at high risk for preterm preeclampsia. Screening and aspirin treatment were performed and begun, respectively, near the end of the first-trimester, which allowed for the maximum benefit of aspirin as suggested by prior studies. Limitations include the lack of follow-up past the early postnatal phase.

Click to read the study, published in NEJM

RELATED REPORTS

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

#VisualAbstract: Apixaban is Superior to Aspirin for Stroke Prevention in People with Subclinical Atrial Fibrillation

Direct oral anticoagulants have similar bleeding risk compared with aspirin

Relevant Reading: Primary, secondary, and tertiary prevention of pre-eclampsia

In-Depth [randomized controlled trial]: This double-blind trial screened 26 941 women with singleton pregnancies, and 2971 (11.0%) were determined to be at high risk for preterm preeclampsia. Of these woman, 1776 were eligible for the study and randomized in a 1:1 ratio to groups receiving 150 mg aspirin (n = 798; 78 withdrew and 2 lost to follow-up) or placebo (n = 822; 72 withdrew and 2 lost to follow-up). Inclusion criteria were age of 18 years or more, singleton pregnancy, live fetus at 11-13 weeks of gestation, and being high-risk (>1 in 100) for preterm preeclampsia. The screening test for preeclampsia risk combined maternal factors, mean arterial pressure, uterine-artery pulsatility index, maternal serum pregnancy-associated plasma protein A, and placental growth factor measured at 11-13 weeks of gestation. The primary outcome was delivery with preeclampsia before 37 weeks of gestation. Secondary outcomes included multiple adverse events of pregnancy before 34 weeks, before 37 weeks, and at or after 37 weeks of gestation, including stillbirth or neonatal death, neonatal complications or therapy, and poor fetal growth.

Preterm preeclampsia occurred in 13 of 798 women (1.6%) in the aspirin group and 35 of 822 (4.3%) of women in the placebo group (odds ratio [OR] of aspirin group, 0.38; 95% confidence interval [CI], 0.20-0.74; p = 0.004). No significant differences were found among any of the secondary outcomes, including adverse outcomes before 34 weeks (OR, 0.62; 95% CI, 0.34-1.14), before 37 weeks (OR, 0.69; 95% CI, 0.46-1.03), or equal to or after 37 weeks of gestation (OR, 1.12; 95% CI, 0.82-1.54). In the aspirin group, serious or any adverse event occurred in 13 (1.6%) and 207 (25.9%) of women, respectively, compared to 26 (3.2%) and 210 (25.5%) of those in the placebo group.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: aspirinpreeclampsia
Previous Post

Little quality evidence on the effectiveness of cannabinoids for treating chronic pain or PTSD

Next Post

On the Move exercise program improved mobility in older adults

RelatedReports

Stent type may not be related to adverse cardiac events after surgery
Cardiology

De-escalating dual antiplatelet therapy may lower major bleeding risk following drug-eluting stent implantation

February 17, 2025
#VisualAbstract: Apixaban is Superior to Aspirin for Stroke Prevention in People with Subclinical Atrial Fibrillation
StudyGraphics

#VisualAbstract: Apixaban is Superior to Aspirin for Stroke Prevention in People with Subclinical Atrial Fibrillation

February 14, 2025
No significant increased risk of bladder cancer with pioglitazone use
Pharma

Direct oral anticoagulants have similar bleeding risk compared with aspirin

February 10, 2025
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Ticagrelor monotherapy reduces bleeding risk compared to dual antiplatelet therapy for patients following coronary stenting

September 25, 2024
Next Post
Reduced gestational weight gain with lifestyle intervention

On the Move exercise program improved mobility in older adults

Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]

Zika virus exposure detected in patients presenting with new neuroinflammatory conditions

Significant percentage of pediatricians dismiss families who refuse vaccines

Negative information about vaccines received during pregnancy delays infant vaccinations

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
  • 2 Minute Medicine Rewind June 30, 2025
  • Weighted vests and resistance training confer similar outcomes for bone density in the elderly
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.